MedTrace Logo

the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human

NCT06490263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-01-20

No results posted yet for this study

Summary

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, and pharmacokinetics of the Mulberry Twig Alkaloids tablets (WH006) in healthy ，overweight and obesity subjects.

Conditions

  • Overweight and Obesity
  • Healthy

Interventions

DRUG

Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects

Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.

DRUG

Mulberry Twig Alkaloids Tablets with single dose in healthy subjects

Parts Two: Administered by swallowing after meals with four distinct dosage groups.

DRUG

Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects

Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.

DRUG

Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects

Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Beijing Wehand-Bio Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ying Gao, MD · Peking University First Hospital

  • Xia Zhao, Master · Peking University First Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2024-10-19
Completion
2024-11-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490263 on ClinicalTrials.gov